Bunge Limited
BG
$113.11
-2.97%
Bunge Global SA is a leading agribusiness solutions company that connects farmers to consumers, delivering essential food, feed, and fuel globally. Operating primarily in the Agricultural Farm Products industry, Bunge's core segments include soybean processing and refining, softseed processing, grain merchandising, and milling. As one of the world's largest oilseed processors and grain traders, Bunge holds a critical position in the global food supply chain, competing with peers like Archer-Daniels-Midland and Cargill. The current investor narrative centers on Bunge's ambitious 2030 targets, including a $15 mid-cycle EPS goal, which signals long-term confidence despite near-term profit headwinds from volatile commodity markets and margin compression. Recent analyst actions have been predominantly positive, with firms like Barclays, JP Morgan, and Morgan Stanley maintaining Overweight ratings, reflecting optimism about the company's strategic direction and shareholder return initiatives.…
BG
Bunge Limited
$113.11
Related headlines
Investment Opinion: Should I buy BG Today?
Based on the analysis, BG is rated a Buy. The consensus recommendation is 'Buy' with an average target price of $141.22, implying a 24.9% upside from the current price of $113.11. The thesis is that the Viterra acquisition will drive significant earnings growth, and the forward PE of 9.97x is attractive relative to the industry average of 22x, suggesting the stock is undervalued on a forward basis.
Sign up to view all
BG 12-Month Price Forecast
The AI assessment leans bullish, driven by the attractive forward valuation and the potential for significant earnings growth from the Viterra acquisition. The low forward PE suggests the market is pricing in a substantial recovery, and the analyst consensus supports this view. However, the confidence is medium due to the thin margins and the cyclical nature of the industry. The stance would be upgraded to high confidence if the company demonstrates margin improvement in the next two quarters, and downgraded to neutral if earnings estimates are revised downward.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bunge Limited's 12-month outlook, with a consensus price target around $141.22 and implied upside of +24.9% versus the current price.
Average Target
$141.22
0 analysts
Implied Upside
+24.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$116 - $150
Analyst target range
Bunge is covered by 9 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.56 (where 1 is Strong Buy and 5 is Sell). The average target price is $141.22, implying an upside of approximately 24.9% from the current price of $113.11. The target price range is $116.00 to $150.00, with the low target representing a modest 2.6% upside and the high target a 32.6% upside. The consensus leans bullish, with no Sell ratings and a majority of Overweight or Buy ratings. Recent institutional actions have been consistently positive, with Barclays, JP Morgan, and Morgan Stanley all maintaining Overweight ratings in early 2026, and UBS reiterating a Buy. The wide spread between the low and high targets ($34) reflects uncertainty around commodity prices and the pace of margin recovery, but the overall sentiment is optimistic, supported by the company's 2030 EPS goal of $15, which would represent a significant increase from current levels.
Bulls vs Bears: BG Investment Factors
Bunge presents a mixed picture: strong strategic moves and a favorable forward valuation are offset by weak current profitability and high leverage. The bull case is supported by the Viterra acquisition, which has dramatically increased scale, and the company's ambitious 2030 EPS target of $15, which suggests management's confidence in long-term growth. However, the bear case is compelling due to the thin margins, negative PEG ratio, and recent price decline, which indicate near-term challenges. The most important tension is whether the expected earnings recovery, driven by Viterra synergies and improved processing margins, will materialize as analysts project. If it does, the stock is undervalued; if not, the current valuation may be too high. Overall, the evidence slightly favors the bull case, given the strong analyst support and the potential for margin expansion, but the risks are significant.
Bullish
- Strong 1-Year Price Performance: BG has delivered a 35.62% return over the past year, significantly outperforming the S&P 500's 20.48% gain. This demonstrates strong momentum and investor confidence in the company's strategic direction.
- Attractive Forward Valuation: The forward PE of 9.97x is substantially lower than the trailing PE of 17.96x, implying the market expects a significant earnings recovery. This is supported by analyst estimates of $12.13 EPS for the next fiscal year, which would represent a major improvement from current levels.
- Analyst Consensus Buy with Upside: With a consensus recommendation of 'Buy' and an average target price of $141.22, the stock offers a potential upside of 24.9% from the current price of $113.11. No analysts have a Sell rating, indicating broad optimism.
- Strategic Viterra Acquisition: The acquisition of Viterra, which closed in mid-2025, has significantly expanded Bunge's scale, with Q1 2026 revenue surging 87.76% year-over-year to $21.86 billion. This positions the company for enhanced market reach and synergies.
Bearish
- Weak Profitability Metrics: Despite the revenue surge, Q1 2026 net income was only $68 million, down from $201 million in Q1 2025. The net margin is a thin 1.16%, and the gross margin is just 4.85%, indicating significant margin compression in the processing businesses.
- High Debt Levels: The debt-to-equity ratio stands at 0.997, indicating a highly leveraged balance sheet. This increases financial risk, especially if commodity prices or margins remain under pressure.
- Negative PEG Ratio: The PEG ratio is -0.46, which is unusual and suggests that earnings growth is expected to be negative in the near term. This could be due to the cyclical nature of the agribusiness industry and the integration costs of Viterra.
- Recent Price Decline: The stock has fallen 8.69% over the past month and is down 6.30% over the past three months, underperforming the S&P 500. This recent weakness may indicate waning momentum or concerns about near-term earnings.
BG Technical Analysis
Bunge's stock has exhibited a strong recovery over the past year, with a 1-year price change of +35.62%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $113.11 sits at approximately 62% of the 52-week range (between $76.01 low and $134.87 high), indicating that while the stock has rebounded substantially from its lows, it remains well below its highs. This positioning suggests a stock in a mature uptrend that has recently pulled back, offering a potential value opportunity if the longer-term trend resumes. The 52-week low of $76.01 was likely set during a period of market stress, and the recovery since then has been robust, but the stock is now trading 16% off its 52-week high of $134.87, which could signal either a healthy consolidation or the beginning of a more significant correction.
Beta
0.65
0.65x market volatility
Max Drawdown
-20.2%
Largest decline past year
52-Week Range
$76-$135
Price range past year
Annual Return
+35.6%
Cumulative gain past year
| Period | BG Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | +3.6% |
| 3m | -6.3% | +2.7% |
| 6m | -7.2% | +11.4% |
| 1y | +35.6% | +18.7% |
| ytd | +22.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BG Fundamental Analysis
Bunge's revenue trajectory has been highly volatile, with the most recent quarter (Q1 2026) reporting revenue of $21.861 billion, a substantial 87.76% year-over-year increase from $11.643 billion in Q1 2025. However, this growth is misleading due to the company's acquisition of Viterra, which closed in mid-2025, significantly expanding its scale. Excluding the acquisition, organic growth would be much more modest. The multi-quarter trend shows revenue fluctuating between $11.6 billion and $23.8 billion, with the Q4 2025 revenue of $23.76 billion being the highest in recent quarters. The revenue growth is primarily driven by the Soybean Processing and Refining segment, which is the company's largest, and the integration of Viterra has boosted volumes across all segments. Despite the revenue surge, profitability has not kept pace, with Q1 2026 net income of only $68 million, down from $201 million in Q1 2025, reflecting margin compression in the processing businesses.
Quarterly Revenue
$21.9B
2026-03
Revenue YoY Growth
+87.8%
YoY Comparison
Gross Margin
3.5%
Latest Quarter
Free Cash Flow
$14000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BG Overvalued?
Given that Bunge's trailing twelve-month net income is positive (approximately $686 million), the PE ratio is the most appropriate primary valuation metric. The trailing PE stands at 17.96x, while the forward PE is significantly lower at 9.97x, implying that the market expects a substantial increase in earnings over the next year. This gap of 44% between trailing and forward PE suggests that analysts anticipate a strong earnings recovery, likely driven by improved processing margins and the full realization of Viterra synergies. The PEG ratio is negative at -0.46, which is unusual and indicates that the earnings growth rate is expected to be negative in the near term, possibly due to the cyclical nature of the agribusiness industry. Compared to the industry average PE of 22x (based on available data), Bunge's trailing PE of 17.96x represents a discount of 18%, which could be justified by its lower net margin of 1.16% versus the industry average of 5%.
PE
18.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are pronounced. Bunge's debt-to-equity ratio of 0.997 indicates a highly leveraged balance sheet, which amplifies the impact of any earnings shortfall. The company's net margin is razor-thin at 1.16%, and Q1 2026 net income of $68 million is a fraction of the $201 million earned in the same quarter last year, highlighting the volatility of its earnings. The negative PEG ratio of -0.46 suggests that earnings growth is expected to be negative in the near term, which could lead to a de-rating if the market loses confidence in the recovery narrative. Additionally, the integration of Viterra brings execution risk, including potential cost overruns and cultural clashes, which could further pressure margins.
FAQ
The key risks of holding BG include: 1) Financial risk from high leverage, with a debt-to-equity ratio of 0.997, which could amplify losses if earnings decline. 2) Operational risk from thin margins, with a net margin of only 1.16%, making the company vulnerable to any cost increases or price declines. 3) Market risk from commodity price volatility, which directly impacts processing margins. 4) Integration risk from the Viterra acquisition, which could face execution challenges. The most severe risk is a prolonged period of weak margins, which could lead to a decline to the 52-week low of $76.01, representing a 32.8% loss from the current price.
The 12-month forecast for BG is moderately bullish, with a base case target range of $115-$130, representing a potential upside of 1.7% to 14.9% from the current price of $113.11. The bull case, with a 30% probability, targets $130-$150, driven by successful Viterra integration and margin recovery. The bear case, with a 20% probability, targets $90-$115, reflecting potential margin compression and integration issues. The most likely scenario is the base case, which assumes gradual margin improvement and stable commodity prices. The average analyst target of $141.22 suggests a 24.9% upside, but this is contingent on the company meeting its earnings estimates.
BG is undervalued on a forward basis, with a forward PE of 9.97x compared to the industry average of 22x. The trailing PE of 17.96x is also below the industry average, but the low net margin of 1.16% suggests that the market is pricing in a significant earnings recovery. The PEG ratio is negative at -0.46, which is unusual and indicates that near-term earnings growth is expected to be negative, possibly due to the cyclical nature of the business. Overall, the stock appears undervalued relative to its forward earnings potential, but the market is cautious about the near-term outlook. If the company meets analyst estimates, the stock could re-rate higher.
BG appears to be a good buy for investors with a medium-to-long-term horizon, given the attractive forward PE of 9.97x and the potential for significant earnings growth from the Viterra acquisition. The analyst consensus is 'Buy' with an average target price of $141.22, implying a 24.9% upside from the current price of $113.11. However, the stock carries risks, including thin margins and high debt, so it is not without volatility. For investors who believe in the company's ability to execute its integration and achieve its 2030 EPS target, the risk/reward is favorable. For those with a shorter-term focus, the recent price decline may present a buying opportunity, but the stock could also continue to fall if earnings disappoint.
BG is more suitable for long-term investment, given its cyclical nature and the potential for significant earnings growth from the Viterra acquisition. The stock has a beta of 0.65, indicating lower volatility than the market, but it is still subject to commodity price swings. The company pays a dividend with a yield of 3.12%, providing some income, but the payout ratio of 56.25% suggests it is sustainable. For long-term investors, the 2030 EPS target of $15 offers a clear growth trajectory, and the current forward PE of 9.97x provides a margin of safety. Short-term traders may find opportunities in the stock's volatility, but the recent price decline of 8.69% over the past month suggests that near-term momentum is negative. A minimum holding period of 2-3 years is recommended to allow the Viterra integration to deliver synergies and for margins to recover.